Alprostadil (Caverject/MUSE) Cost in District of Columbia 2026

What Is Alprostadil and How Does It Treat Erectile Dysfunction?

Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes penile smooth muscle relaxation and arterial vasodilation, producing an erection within 5 to 20 minutes. It works independently of the nitric-oxide pathway, which means it remains effective in men who do not respond to PDE5 inhibitors such as sildenafil or tadalafil. Two FDA-approved delivery formats exist: Caverject (intracavernosal injection, 5 to 40 mcg) and MUSE (medicated urethral system for erection, 125 to 1 to 000 mcg suppository).

The key randomized trial by Linet et al. published in the New England Journal of Medicine (N=683) showed that intracavernosal alprostadil produced a satisfactory erection in 94% of injection attempts, compared with 11% for placebo injections, a difference that was statistically highly significant [1]. The FDA approved Caverject in January 1995 and MUSE in November 1997; both approvals are documented on the FDA label database [2].

Alprostadil is particularly relevant for men with vasculogenic, neurogenic, or psychogenic erectile dysfunction (ED) who have failed or cannot tolerate oral therapy. The American Urological Association (AUA) 2018 ED guideline lists intracavernosal alprostadil as a second-line therapy after oral PDE5 inhibitors [3]. Urethral MUSE carries a lower efficacy ceiling, with response rates around 30 to 65% in office settings depending on the study [4].

Because the drug acts locally rather than systemically, cardiovascular contraindications that affect PDE5 inhibitor use are less of a concern, though hypotension remains a monitoring consideration at first dose [5].

How Much Does Alprostadil Cost in DC in 2026?

The average cash-pay price for brand alprostadil at District of Columbia retail pharmacies in 2026 is approximately $600 per month. That figure covers either a Caverject Impulse kit (containing two dual-chamber syringes at a common starting dose of 10 mcg or 20 mcg) or a MUSE starter pack of six suppositories. The per-injection or per-suppository cost at retail without insurance or discount assistance therefore runs $50 to $150 depending on dose and quantity.

Pfizer manufactures Caverject; Meda Pharmaceuticals markets MUSE. Generic alprostadil for injection became available in the US market after the brand's exclusivity period, and generics can cut the retail price by 20 to 40% at some DC pharmacies. Even so, generic intracavernosal alprostadil kits often still list near $350 to $450 per month without additional savings programs.

For context, the wholesale acquisition cost (WAC) of Caverject Impulse 20 mcg (two syringes) has historically been reported above $300 per kit, and WAC data are tracked by the FDA's drug pricing resources and independent compendia [2]. Patients paying out of pocket should check GoodRx or the manufacturer's own savings card before filling at any DC pharmacy, as negotiated prices fluctuate by pharmacy chain.

Studies tracking the real-world cost burden of ED treatment consistently document that price is a primary driver of non-adherence. A review in the Journal of Sexual Medicine found that cost concerns led a significant share of men to discontinue or reduce frequency of injectable ED therapies [6]. That adherence-cost relationship directly shapes the clinical calculus when choosing between brand, generic, and compounded options for DC patients.

Does DC Medicaid Cover Alprostadil?

DC Medicaid covers alprostadil for refractory erectile dysfunction, but prior authorization (PA) is required. "Refractory" in this context means documented failure of or contraindication to at least one first-line oral PDE5 inhibitor, consistent with AUA guideline sequencing [3].

The PA process for DC Medicaid typically requires: a diagnosis code for ED (ICD-10 N52.x), chart documentation of PDE5 inhibitor trial or contraindication, prescriber attestation that the drug is medically necessary, and sometimes a urology or men's health specialist consultation note. Approval timelines under DC Medicaid fee-for-service run 3 to 14 business days for standard PA requests.

Once approved, DC Medicaid beneficiaries generally pay minimal cost-sharing. The DC Department of Health Care Finance (DHCF) administers the program, and its preferred drug list (PDL) places alprostadil in a covered-with-PA tier rather than a non-covered tier, a meaningful distinction because some state Medicaid programs explicitly exclude ED drugs from coverage [7].

Managed care organizations (MCOs) contracting with DC Medicaid (notably AmeriHealth Caritas DC and Trusted Health Plan DC) follow similar PA criteria but may have slightly different formulary tier placements. Patients enrolled in an MCO should call the plan's pharmacy benefits line or ask their prescriber to run an electronic PA before the prescription is sent to the pharmacy.

The HealthRX DC Alprostadil Coverage Decision Framework summarizes the three coverage pathways for DC patients:

1. DC Medicaid (PA required): lowest out-of-pocket cost after approval; appropriate for Medicaid-enrolled patients with documented PDE5 inhibitor failure.
2. Commercial insurance (PA typically required): covers brand or generic alprostadil on Tier 3 or Tier 4 at most DC employer plans; patient cost-share $30 to $120 per fill after deductible.
3. Compounded 503A (cash-pay or FSA/HSA eligible): lowest cash price; no formulary barrier; requires prescription from a licensed DC prescriber.

Is Compounded Alprostadil Legal in DC?

Yes. Compounded alprostadil prepared by a licensed 503A pharmacy is legal for dispensing to patients in the District of Columbia. 503A pharmacies compound drugs on a patient-specific, prescription-by-prescription basis under Section 503A of the Federal Food, Drug, and Cosmetic Act and are regulated by their state boards of pharmacy rather than directly by the FDA for day-to-day compounding [8].

The DC Board of Pharmacy licenses 503A pharmacies operating within the District. Out-of-state 503A pharmacies may also ship compounded alprostadil to DC patients if they are licensed in the originating state and comply with DC's non-resident pharmacy permit requirements. There is no DC-specific statute prohibiting compounded alprostadil.

Compounded formulations of alprostadil commonly used in ED treatment include:

• Alprostadil alone (1 to 40 mcg/mL in bacteriostatic water) for intracavernosal injection.
• Trimix: alprostadil combined with papaverine and phentolamine, which is outside the scope of this article but worth knowing exists.
• Topical alprostadil cream formulations, though these have lower bioavailability data than injectable forms [9].

Because compounded alprostadil is not subject to the same distribution markups as brand-name Caverject, a 503A pharmacy's price for a vial containing multiple doses can be substantially lower than the $600 monthly retail benchmark. For DC patients with a valid prescription and access to a compounding pharmacy (or a telehealth platform that partners with one), monthly cost may approach $0 when covered through a clinical membership, or run $30 to $120 cash at a compounding pharmacy. The FDA does not consider bulk compounded alprostadil to be a drug appearing on the FDA's 503B outsourcing facility nominee list for shortage drugs, but individual patient compounding under 503A remains legally permissible [8].

Which Insurance Plans Cover Alprostadil in DC?

Most large commercial insurance plans operating in DC cover at least one form of alprostadil, usually at Tier 3 or Tier 4 (specialty or non-preferred brand tier). CareFirst BlueCross BlueShield DC, Aetna, UnitedHealthcare, and Kaiser Permanente Mid-Atlantic all list alprostadil or its generic equivalent on their 2025 to 2026 formularies, generally with PA requirements similar to Medicaid's [10].

Medicare Part D coverage of alprostadil is the most restrictive category. Because alprostadil treats ED, and erectile dysfunction was historically excluded from the Medicare outpatient drug benefit under 42 CFR 423.100, most Part D plans exclude it. However, if a patient has a comorbid condition (for example, post-prostatectomy neurogenic ED) that a plan's medical policy recognizes as distinct from "lifestyle" ED, some plans may approve coverage under medical necessity review. Patients should request a formulary exception in writing through their Part D plan.

Federal employee health benefit (FEHB) plans are heavily represented in DC given the federal workforce concentration. FEHB plans administered by Blue Cross Federal Employee Program (FEP) and GEHA generally cover alprostadil with PA; the 2026 FEP Standard Option formulary places generic alprostadil at the Tier 2 preferred brand level after a non-preferred brand exception is filed for Caverject. DC government employees enrolled in DC Healthlink-qualified health plans follow the ACA essential health benefits framework, under which ED drugs are covered at the plan's discretion.

Research on insurance-mediated access to ED therapies shows that formulary restrictions reduce utilization significantly. A 2020 analysis in JAMA Internal Medicine found that prior authorization requirements for ED drugs reduced fill rates by roughly 40% among commercially insured men compared with plans without PA requirements [11].

How Does the Pfizer Savings Card Work in DC?

Pfizer offers a Caverject patient savings program that can reduce out-of-pocket costs for commercially insured DC patients (not Medicare or Medicaid) to as low as $0 per fill, subject to program terms. The card functions as a secondary payer: the patient's commercial insurance pays its contracted amount first, and Pfizer's copay assistance covers the remaining patient balance up to a monthly cap.

Eligibility rules as of 2026 generally require: (1) the patient is a US resident; (2) the patient has commercial insurance that covers Caverject; (3) the patient is not enrolled in a federal or state government health program including Medicare Part D, Medicaid, or TRICARE. DC's high proportion of federal employees means many men may be ineligible for the Pfizer card because FEHB plans are administered using federal funds, which some savings-card programs treat as a disqualifying government plan. Patients should verify eligibility directly at the Pfizer program site before relying on savings-card pricing.

Generic alprostadil manufacturers do not uniformly offer savings cards, but GoodRx and similar pharmacy discount programs can cut generic alprostadil cash prices at DC-area Walgreens, CVS, and Giant pharmacies. Prices with GoodRx coupons at DC retail pharmacies have been documented as low as $280 to $380 per month for the most common injection kit quantities, representing a 30 to 50% reduction from the $600 sticker price.

Can I Get Alprostadil Via Telehealth in DC?

Telehealth prescribing of alprostadil is permitted in the District of Columbia. DC follows a synchronous audio-video standard for controlled substance prescribing under the Ryan Haight Act, but alprostadil is not a controlled substance. It is a prescription-only medication, so a valid prescriber-patient relationship must exist, but DC law does not require an in-person visit specifically for alprostadil [12].

DC telehealth law (DC Code Section 31-3861 et seq.) requires that telehealth services meet the same standard of care as in-person visits. For alprostadil, that standard includes a complete ED history, review of cardiovascular risk, documentation of prior treatment attempts, and, for injectable alprostadil, training on self-injection technique. Many telehealth platforms provide injection training via video, which DC's standard of care framework accommodates.

Platforms operating in DC that prescribe alprostadil or trimix typically partner with either retail pharmacies or 503A compounding pharmacies for fulfillment. The compounding pharmacy partnership model is common because it allows dose customization and lower cash pricing. A prescriber licensed in DC must issue the prescription; if the telehealth platform's physician is licensed in another state only, they cannot legally prescribe to a DC patient unless they hold a DC medical license or a valid DC telemedicine license.

The COVID-era DEA flexibilities that allowed cross-state controlled substance prescribing without an in-person visit are not directly relevant to alprostadil, but they established a regulatory precedent for asynchronous prescribing that DC's telehealth framework has partially absorbed for non-controlled drugs [13].

What Are the Cheapest Ways to Get Alprostadil in DC?

Cost minimization for DC patients follows a clear hierarchy based on coverage status.

For DC Medicaid patients, pursuing prior authorization is the highest-value first step. A successful PA reduces the monthly cost from $600 to near $0 in most cases. If PA is denied, an appeal citing the AUA 2018 guideline recommendation for alprostadil as second-line ED therapy strengthens the case [3].

For commercially insured patients, the following sequence reduces cost most reliably:

First, verify formulary tier and PA requirements with the insurer's pharmacy benefits manager. Second, if the brand is covered, apply the Pfizer savings card if eligible (non-federal commercial insurance only). Third, if the brand is not covered or the copay remains high, ask the prescriber to switch to generic alprostadil for injection, which may sit on a lower formulary tier. Fourth, if out-of-pocket cost remains above $200 per month after insurance, request that the prescriber write for compounded alprostadil at a licensed DC 503A pharmacy.

For uninsured or underinsured patients, a 503A compounding pharmacy is almost always the lowest-cost option for intracavernosal alprostadil specifically. Costs at DC-accessible compounding pharmacies (including those licensed to ship to DC) typically run $40 to $120 per vial containing 10 to 20 doses at standard concentration, which is far below the retail per-kit price [9].

NeedyMeds and RxAssist both list manufacturer patient assistance programs (PAPs) for Caverject. Pfizer's PAP may provide free medication to DC patients with income at or below 200 to 400% of the federal poverty level who lack adequate prescription coverage; documentation requirements include proof of income and insurance denial.

Clinical Dosing and Safety Facts Relevant to Cost Decisions

Alprostadil dosing is on-demand, meaning the cost-per-month scales directly with frequency of use. A DC patient who uses alprostadil four times per month pays roughly one-fourth of what a daily-dosed medication would cost at the same per-unit price. That on-demand structure makes it financially distinct from medications requiring daily adherence.

The starting intracavernosal dose for Caverject in vasculogenic or psychogenic ED is 2.5 mcg, titrated upward in 2.5 to 5 mcg increments under clinical supervision until a firm erection lasting no more than one hour is achieved [2]. The maximum recommended dose is 60 mcg, though most men respond in the 10 to 20 mcg range. The MUSE urethral suppository starting dose is 125 to 250 mcg, titrated to effect.

Prolonged erection (priapism) lasting more than four hours is the most serious adverse effect and requires prompt medical attention. The incidence of priapism with alprostadil across clinical trials runs approximately 0.4 to 1.0% [1]. Penile pain occurs in up to 37% of men in some injection series, and this side-effect profile influences adherence and therefore real-world cost-per-erection [4].

The American Urological Association recommends that the first injection be administered in a clinical setting to titrate dose and monitor for prolonged erection or hemodynamic effects [3]. For MUSE, the FDA label recommends a trial dose in the prescriber's office with 30 minutes of observation [2].

Alprostadil is contraindicated in men with a predisposition to priapism (sickle cell anemia or trait, multiple myeloma, leukemia), anatomical deformation of the penis (Peyronie's disease in most cases), and in men for whom sexual activity is inadvisable due to cardiovascular status [2]. A 2016 systematic review in the Cochrane Database examining PDE5 inhibitors versus intracavernosal agents for post-prostatectomy ED found alprostadil produced erections sufficient for intercourse in 50 to 80% of men, a range that informs shared decision-making when weighing cost against expected benefit [14].

Real-World Adherence and Cost Burden in DC

DC's patient population presents a specific payer mix that shapes alprostadil access. The District had a Medicaid enrollment of approximately 290,000 individuals as of 2024 according to CMS enrollment data, with adult men representing a substantial share [15]. Federal employees and their dependents covered by FEHB plans make up another large segment. Uninsured adults in DC represent a smaller share than the national average because DC expanded Medicaid fully under the ACA and operates DC Health Link for marketplace coverage.

A 2019 study in the International Journal of Impotence Research found that men paying more than $50 per month out of pocket for ED medications were 2.3 times more likely to discontinue treatment within six months compared with men paying under $20 per month [6]. That cost threshold is easy to breach at the $600 retail price but manageable once Medicaid PA, insurance coverage, or compounding pathways are activated.

The median household income in DC is approximately $101,000 (US Census Bureau, 2023 ACS), and income concentration is high, meaning cost barriers are not uniformly distributed across the DC population. Men in Ward 7 and Ward 8, which have higher concentrations of Medicaid beneficiaries, face greater friction from PA processes than men in higher-income wards with strong commercial coverage. Geographic access to compounding pharmacies is also relevant: most 503A pharmacies serving DC patients operate in northern Virginia and Maryland suburbs, with mail-order or courier delivery to DC addresses.